{
    "clinical_study": {
        "@rank": "14772", 
        "acronym": "eTRIS", 
        "arm_group": [
            {
                "arm_group_label": "edoxaban tosylate", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "heparin/warfarin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Assess the relative change in thrombus volume as determined by two assessments (Baseline and\n      Day 14-21) with magnetic resonance imaging (MRI) in subjects with deep-vein thrombosis (DVT)\n      treated with either an edoxaban monotherapy regimen or a low molecular weight (LMW)\n      heparin/warfarin regimen."
        }, 
        "brief_title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Deep Vein Thrombosis", 
            "Venous Thrombosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "The classical management of patients with venous thromboembolism (VTE) consists of an\n      initial treatment of at least five days of a (LMW) heparin followed by long-term treatment\n      with a vitamin K antagonist (VKA), such as warfarin.     The eTRIS study will address the\n      clinically important question of whether edoxaban monotherapy, without concomitant (LMW)\n      heparin at the time of treatment initiation is comparable to or better than standard\n      treatment with (LMW) heparin/warfarin therapy in subjects with acute symptomatic DVT as\n      assessed by the relative change from baseline in thrombus volume (measured by MRI) at Day\n      14-21."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects older than the minimum legal adult age (country specific)\n\n          -  Acute symptomatic proximal DVT involving the popliteal, femoral or iliac veins\n             confirmed by compression ultrasonography (CUS) or other appropriate imaging\n             techniques (such as venography or spiral/contrast CT) with symptom onset < or =\n             1week prior to randomization\n\n          -  Able to provide signed informed consent\n\n        Exclusion Criteria:\n\n          -  Concomitant pulmonary embolism known to the investigator at the time of randomization\n\n          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat\n             the  current episode of DVT\n\n          -  Indication for warfarin other than DVT\n\n          -  More than 48 hours pre-treatment with therapeutic dosages of anti-coagulant treatment\n             (LMWH, UFH, fondaparinux, VKA, factor Xa inhibitor or other anti coagulant per local\n             labeling) prior to randomization to treat the current episode\n\n          -  Treatment with any investigational drug within 30 days prior to randomization\n\n          -  Calculated CrCL < 30 mL/min\n\n          -  Significant liver disease (e.g., acute hepatitis, chronic active hepatitis,\n             cirrhosis) or ALT > or = 2 times the upper limit of normal (ULN), or total bilirubin\n             (TBL) > or = to 1.5 times the ULN (however subjects whose elevated TBL is due to\n             known Gilbert's syndrome may be included in the study)\n\n          -  Subjects with active cancer for whom long term treatment with (LMW) heparin is\n             anticipated\n\n          -  Life expectancy < 3 months\n\n          -  Active bleeding or high risk for bleeding contraindicating treatment with (LMW)\n             heparin or warfarin\n\n          -  Uncontrolled hypertension as judged by the Investigator (e.g., systolic blood\n             pressure > 170 mmHg or diastolic blood pressure > 100 mmHg despite antihypertensive\n             medications confirmed by repeat measurement)\n\n          -  Women of childbearing potential without proper contraceptive measures (i.e., a method\n             of contraception with a failure rate < 1 % during the course of the study including\n             the observational period) and women who are pregnant or breast feeding\n\n          -  Any contraindication listed in the local labeling of LMWH, UFH, or warfarin\n\n          -  Chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs)\n             including both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX- 2) inhibitors for\n             > or = 4 days/week anticipated to continue during the study.\n\n          -  Treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet\n             therapy (any two antiplatelet agents including aspirin plus any other oral or\n             intravenous [IV] antiplatelet drug) anticipated to continue during the study\n\n          -  Treatment with P-gp inhibitors is not permitted at the time of randomization;\n             subsequent use is permitted, with a dose reduction in the edoxaban monotherapy\n             treatment arm.\n\n          -  Known history of positive Hepatitis B antigen or Hepatitis C antibody\n\n          -  Subjects with any condition that, as judged by the investigator, would put the\n             subject at increased risk of harm if he/she participated in the study; including, but\n             not limited to, subjects at increased risk of harm if given a gadolinium-based\n             contrast agent such as gadofosveset trisodium (Ablavar\u00ae)\n\n          -  Subjects for whom MRI would be contraindicated (e.g., subjects with metal implants)\n             or for whom the use of a gadolinium-based contrast agent such as gadofosveset\n             trisodium (Ablavar\u00ae) would be contraindicated\n\n          -  Subject has previously entered this study or another edoxaban study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662908", 
            "org_study_id": "DU176b-D-U211"
        }, 
        "intervention": [
            {
                "arm_group_label": "edoxaban tosylate", 
                "description": "edoxaban tosylate (DU-176b), film-coated for oral use,  90 mg QD for 10 days (\u00b12 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment", 
                "intervention_name": "edoxaban tosylate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "heparin/warfarin", 
                "description": "enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.", 
                "intervention_name": "enoxaparin/unfractionated heparin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "heparin/warfarin", 
                "description": "tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.", 
                "intervention_name": "warfarin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin", 
                "Warfarin", 
                "Enoxaparin", 
                "Heparin, Low-Molecular-Weight"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dothan", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montgomery", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlantis", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Myers", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jonesboro", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paducah", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Covington", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annapolis", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randallstown", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Butte", 
                        "country": "United States", 
                        "state": "Montana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grand Island", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maumee", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camp Hill", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ephrata", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sellersville", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rapid City", 
                        "country": "United States", 
                        "state": "South Dakota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fredericksburg", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Market", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenfield Park", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis - Edoxaban Thrombus Reduction Imaging Study", 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Samuel Z Goldhaber, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Relative change from baseline in thrombus volume assessed by MRI", 
            "safety_issue": "No", 
            "time_frame": "14 - 21 days from time of randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662908"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding)", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 Visit to Day 10 Visit, and during treatment up to 3 days after interrupting or stopping study drug"
            }, 
            {
                "measure": "Recurrence of VTE", 
                "safety_issue": "No", 
                "time_frame": "90 days from time of randomization"
            }, 
            {
                "measure": "Major adverse cardiovascular events (MACE) defined as a composite of non-fatal myocardial infarction (MI), non-fatal stroke, non-fatal systemic embolic event (SEE) and cardiovascular death.", 
                "safety_issue": "Yes", 
                "time_frame": "90 days from time of randomization"
            }, 
            {
                "measure": "Change from baseline in the presence or absence of thrombus by vessel", 
                "safety_issue": "No", 
                "time_frame": "14 - 21 days from time of randomization"
            }
        ], 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}